{"log_id": 5044869933772992216, "direction": 0, "words_result_num": 50, "words_result": [{"probability": {"variance": 0.014113, "average": 0.960351, "min": 0.402134}, "location": {"width": 865, "top": 188, "height": 34, "left": 161}, "words": "过血液透析清除阿德福韦,阿德福韦经体重校正后的血液透析清除率中位数为104 ml/min.来"}, {"probability": {"variance": 0.001816, "average": 0.981508, "min": 0.828554}, "location": {"width": 311, "top": 225, "height": 27, "left": 163}, "words": "进行腹膜透析清除阿德福韦的研究"}, {"probability": {"variance": 2e-06, "average": 0.998506, "min": 0.995961}, "location": {"width": 112, "top": 259, "height": 25, "left": 169}, "words": "【药理毒理】"}, {"probability": {"variance": 0.019213, "average": 0.926706, "min": 0.424053}, "location": {"width": 820, "top": 281, "height": 35, "left": 208}, "words": "作用机制:本品阿德福韦酯是一种口服抗病毒药。德福在体内代谢成阿德褂韦,阿德"}, {"probability": {"variance": 0.012132, "average": 0.970018, "min": 0.389254}, "location": {"width": 863, "top": 313, "height": 34, "left": 164}, "words": "福韦是一种单磷酸腺苷的无环核苷类似物,在细胞激酶的作用下进一步被游酸化为有性的代谢"}, {"probability": {"variance": 0.004909, "average": 0.972248, "min": 0.704938}, "location": {"width": 863, "top": 343, "height": 37, "left": 164}, "words": "产物即阿德福韦二磷酸盐。阿德福韦二磷酸盐通过下列两种方式来抑制 HBV DNA多聚酶(逆转"}, {"probability": {"variance": 0.00209, "average": 0.98198, "min": 0.711413}, "location": {"width": 844, "top": 375, "height": 36, "left": 164}, "words": "录酶):一是与自然底物脱氧腺苷三磷酸竞争,二是整合到病毒DNA后引起DNA链延长终止"}, {"probability": {"variance": 0.014182, "average": 0.951902, "min": 0.474032}, "location": {"width": 865, "top": 406, "height": 38, "left": 165}, "words": "阿德福韦二磷酸盐对 HBV DNA多聚酶的抑制常数(Ki)是0.1μM,但对人类DNA多聚酶a和"}, {"probability": {"variance": 0.018612, "average": 0.944119, "min": 0.367336}, "location": {"width": 479, "top": 443, "height": 30, "left": 168}, "words": "Y的抑制作用较弱,Ki值分别为1.181M和0.97M"}, {"probability": {"variance": 0.01533, "average": 0.930487, "min": 0.500497}, "location": {"width": 821, "top": 470, "height": 35, "left": 206}, "words": "抗病毒活性:在转染HBV的人肝瘤细胞系中,阿德福排制50%病DNA复制的浓度(IC50"}, {"probability": {"variance": 0.000379, "average": 0.983197, "min": 0.940961}, "location": {"width": 139, "top": 511, "height": 25, "left": 167}, "words": "为0.2~2.5μM"}, {"probability": {"variance": 0.008277, "average": 0.956629, "min": 0.564069}, "location": {"width": 825, "top": 532, "height": 34, "left": 208}, "words": "耐药性:对接受阿德福韦潍治疗仍然可检测到血清 HBV DNA的患者进行了长期耐药性分析"}, {"probability": {"variance": 0.01746, "average": 0.926664, "min": 0.441632}, "location": {"width": 865, "top": 562, "height": 37, "left": 167}, "words": "(6~144周),确定了rtN236T和rtA18IV交异与阿德福韦耐药有关。体外研究发现rtN236T变异"}, {"probability": {"variance": 0.008332, "average": 0.96839, "min": 0.485636}, "location": {"width": 863, "top": 594, "height": 35, "left": 169}, "words": "导致HBV对阿德福韦的敏感性降低4~14倍,产生这种变异的616名患者的血清 HBV DNA发生"}, {"probability": {"variance": 0.014523, "average": 0.939489, "min": 0.471845}, "location": {"width": 866, "top": 624, "height": 37, "left": 168}, "words": "反跳。rAI8IV变异导致HBV对阿德福韦的敏感性降低2.5~3倍,产生这种变异的23名患者发"}, {"probability": {"variance": 0.015219, "average": 0.931223, "min": 0.367887}, "location": {"width": 840, "top": 654, "height": 37, "left": 169}, "words": "生反跳。与阿德福韦耐药相关的变异发生率0~48周为0%(01629),499周为2%(61293),97"}, {"probability": {"variance": 0.004869, "average": 0.967659, "min": 0.668808}, "location": {"width": 431, "top": 688, "height": 34, "left": 174}, "words": "144周为1.8%(3163),3年的累计发生率为3.9%"}, {"probability": {"variance": 0.023455, "average": 0.902794, "min": 0.450232}, "location": {"width": 807, "top": 715, "height": 35, "left": 212}, "words": "交叉耐药性:在 HBV DNA多聚酶基因上含对拉米夫定耐药相关突变(rtL180M,tM20t"}, {"probability": {"variance": 0.014826, "average": 0.912745, "min": 0.48069}, "location": {"width": 863, "top": 744, "height": 39, "left": 174}, "words": "rM204V,rtL180M+rtM204V,rtVI73L)的重组HBV变异株,在体外对阿德福敏感。在拉米"}, {"probability": {"variance": 0.001969, "average": 0.976763, "min": 0.757797}, "location": {"width": 865, "top": 776, "height": 37, "left": 171}, "words": "夫定耐药相关变异HBV的患者中,阿德福韦也显示了抗HBV作用,其血清 HBV DNA下降的"}, {"probability": {"variance": 0.027049, "average": 0.893726, "min": 0.410056}, "location": {"width": 864, "top": 807, "height": 37, "left": 173}, "words": "中位数为4.3log10拷贝数/毫升。含DNA多聚酶突变(rtTI28N和rR153Q或nW53Q,与乙肝炎"}, {"probability": {"variance": 0.011744, "average": 0.965311, "min": 0.433459}, "location": {"width": 535, "top": 841, "height": 34, "left": 174}, "words": "免疫球蛋白耐药相关)的HBV变异株,在体外对阿德福"}, {"probability": {"variance": 0.026919, "average": 0.891841, "min": 0.354695}, "location": {"width": 864, "top": 862, "height": 41, "left": 173}, "words": "耐药相关的rN236T突变的HBV对拉米夫定的敏感性降低理号存与耐关的"}, {"probability": {"variance": 0, "average": 0.93003, "min": 0.93003}, "location": {"width": 23, "top": 857, "height": 24, "left": 1057}, "words": "粤"}, {"probability": {"variance": 0.019711, "average": 0.94506, "min": 0.377062}, "location": {"width": 451, "top": 904, "height": 32, "left": 184}, "words": "A8V突变的HBV对拉米夫定的敏感性降低3倍"}, {"probability": {"variance": 0.051425, "average": 0.794911, "min": 0.393592}, "location": {"width": 120, "top": 916, "height": 33, "left": 827}, "words": "2008050"}, {"probability": {"variance": 0.021058, "average": 0.926639, "min": 0.636415}, "location": {"width": 92, "top": 940, "height": 24, "left": 217}, "words": "毒理研究:"}, {"probability": {"variance": 0.016287, "average": 0.968186, "min": 0.370463}, "location": {"width": 503, "top": 963, "height": 32, "left": 217}, "words": "慢性毒性:在动物试验中,以组织学改变和或尿素"}, {"probability": {"variance": 0.067285, "average": 0.761895, "min": 0.360789}, "location": {"width": 205, "top": 962, "height": 46, "left": 880}, "words": "斗执行"}, {"probability": {"variance": 0.008894, "average": 0.970658, "min": 0.523755}, "location": {"width": 536, "top": 995, "height": 34, "left": 178}, "words": "是阿德福韦酯的主要剂量限制性毒性反应。在动物试验中观"}, {"probability": {"variance": 0.007686, "average": 0.96382, "min": 0.60653}, "location": {"width": 317, "top": 1031, "height": 27, "left": 178}, "words": "的人治疗量(10mg天)下的3~10倍"}, {"probability": {"variance": 0.074686, "average": 0.671146, "min": 0.397858}, "location": {"width": 50, "top": 1019, "height": 29, "left": 936}, "words": "专"}, {"probability": {"variance": 0.01425, "average": 0.947866, "min": 0.501328}, "location": {"width": 823, "top": 1056, "height": 32, "left": 219}, "words": "遗传毒性:在体外小鼠淋巴细胞瘤试验中(有或无代谢活化),阿德韦有致突变用。在"}, {"probability": {"variance": 0.031585, "average": 0.915272, "min": 0.391159}, "location": {"width": 862, "top": 1086, "height": 33, "left": 179}, "words": "人外周血淋巴细胞试验中,无代谢活化时,阿德福韦酯能诱导染色体变。阿德精书酯小鼠核"}, {"probability": {"variance": 0.016271, "average": 0.956499, "min": 0.450424}, "location": {"width": 636, "top": 1119, "height": 31, "left": 180}, "words": "试验结果为阴性,阿德福市在有减无代谢酒化时Ames试验结果为阴性"}, {"probability": {"variance": 0.007374, "average": 0.9718, "min": 0.507753}, "location": {"width": 765, "top": 1150, "height": 28, "left": 220}, "words": "生殖毒性:当暴露量大约为人治疗剂量下暴露量的19倍时,来见对大鼠生育力的影响"}, {"probability": {"variance": 0.020036, "average": 0.928354, "min": 0.48325}, "location": {"width": 935, "top": 1174, "height": 52, "left": 178}, "words": "经口给予阿德福韦酯(暴露量分别约为人治疗剂量10mg天下的23和40倍),未见胚输囊性和致麟背校"}, {"probability": {"variance": 0.004835, "average": 0.979666, "min": 0.560061}, "location": {"width": 926, "top": 1195, "height": 51, "left": 181}, "words": "作用。妊娠大鼠静脉注射给予阿德福韦,在能产生明显母体毒性的剂量时相当人体暴露量的"}, {"probability": {"variance": 0.001451, "average": 0.980629, "min": 0.82944}, "location": {"width": 858, "top": 1241, "height": 31, "left": 185}, "words": "38倍),胚胎毒性和胎仔畸形(全身性水肿,眼泡凹陷,脐疝和尾巴扭结)的发生率增加在静脉注"}, {"probability": {"variance": 0.004899, "average": 0.970339, "min": 0.705872}, "location": {"width": 406, "top": 1274, "height": 29, "left": 180}, "words": "射剂量相等于人暴露量12倍时未见不良影响"}, {"probability": {"variance": 0.012022, "average": 0.951728, "min": 0.53333}, "location": {"width": 807, "top": 1302, "height": 28, "left": 221}, "words": "致癌性:小鼠和大鼠经口给予阿德福书酯,剂量分别稚当于人治疗剂量时暴露量的10倍科"}, {"probability": {"variance": 0.000137, "average": 0.992542, "min": 0.961056}, "location": {"width": 186, "top": 1333, "height": 27, "left": 185}, "words": "倍时,未见致癌作用"}, {"probability": {"variance": 2e-06, "average": 0.999081, "min": 0.995704}, "location": {"width": 128, "top": 1367, "height": 24, "left": 195}, "words": "【药代动力学】"}, {"probability": {"variance": 0.055669, "average": 0.669954, "min": 0.434012}, "location": {"width": 79, "top": 1342, "height": 53, "left": 1043}, "words": "约"}, {"probability": {"variance": 0.002933, "average": 0.976268, "min": 0.743368}, "location": {"width": 823, "top": 1388, "height": 32, "left": 224}, "words": "据国外文献报道:阿德福韦酯是活性成份阿德福韦的前体药物。口服给药后,阿德福韦"}, {"probability": {"variance": 0.005292, "average": 0.971888, "min": 0.654589}, "location": {"width": 932, "top": 1418, "height": 32, "left": 183}, "words": "速地转化为阿德福韦。健康志愿者与慢性乙肝病人服用阿德福韦酯的药代动力学相似口服德"}, {"probability": {"variance": 0.014706, "average": 0.959053, "min": 0.399354}, "location": {"width": 889, "top": 1452, "height": 29, "left": 183}, "words": "福韦酯10mg阿德福韦的生物利用度为59%。慢性乙型肝炎患者单剂口服本品10mg后达到血"}, {"probability": {"variance": 0.015748, "average": 0.943388, "min": 0.482613}, "location": {"width": 845, "top": 1483, "height": 26, "left": 184}, "words": "峰浓度(Cmax)的中位数时间为1.75小时(范围:0.58~4.0小时)。Cmax的中位数为16.709.66"}, {"probability": {"variance": 0.023114, "average": 0.904675, "min": 0.440916}, "location": {"width": 860, "top": 1514, "height": 27, "left": 187}, "words": "3.56)ng/ml,AUCo的中位数为204.40(109.75356.05)nghm血浆阿德福市以二房方式"}, {"probability": {"variance": 3.5e-05, "average": 0.992807, "min": 0.9857}, "location": {"width": 101, "top": 1603, "height": 38, "left": 1072}, "words": "仅供存档"}], "language": 3}